BUFFALO, N.Y. — A Buffalo biotech company is moving ahead with plans for a brain cancer immunotherapy vaccine after receiving fast track approvals from the FDA. MimiVax LLC, which spun off from ...

MimiVax receives fast-track designation for brain cancer therapy

The device is indicated for newly diagnosed glioblastoma.

FDA Grants Fast Track Designation for MimiVax’s SurVaxM

MimiVax LLC, which spun off from Roswell Park Comprehensive Cancer Center, has been developing its SurVaxM therapy for several years for treatment of glioblastoma. The fast-track designation from ...

MimiVax LLC, which spun off from Roswell Park Comprehensive Cancer Center, has been developing its SurVaxM therapy for several years for treatment of glioblastoma.

The FDA Fast Track Designation is “designated to facilitate the development and expedite the review of drugs to treat serious medical conditions and fulfill unmet medical need,” according to MimiVax. "The receipt of Fast Track Designation affirms the ...

FDA Grants Fast Track Designation to SurVaxM for Newly Diagnosed Glioblastoma

The designation awarded to MimiVax Inc. provides more extensive, accelerated access to FDA resources supporting development of SurVaxM, which originated at Roswell Park. BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation ...

Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation

The designation awarded to MimiVax Inc. provides more extensive, accelerated access to FDA resources supporting development of SurVaxM, which originated at Roswell Park. BUFFALO, N.Y., Oct. 14 ...

Credit: Pornpak Khunatorn via Getty Images. The US Food and Drug Administration (FDA) has granted fast track designation to MimiVax’s SurVaxM vaccine for the treatment of newly diagnosed glioblastoma (nGBM). The FDA’s decision was based on results from ...

FDA fast tracks MimiVax’s glioblastoma vaccine SurVaxM

The US Food and Drug Administration (FDA) has granted fast track designation to MimiVax’s SurVaxM vaccine for the treatment of newly diagnosed glioblastoma (nGBM). The FDA’s decision was ...

MimiVax is focused on completing the Phase 2b SURVIVE study and securing funding necessary to bring SurVaxM through the FDA approval process. Glioblastoma is a rare disease with great unmet ...

Stories, News & Mentions about MIMIVAX

Trending Topics

Classic

Neon Noir

Minty

Newspaper

HN StartUps